Natalia Wolińska

Natalia Wolińska

Auto-generated profile, based on publicly available information

Natalia Wolińska

Faculty of Medicine and Health Sciences, Collegium Medicum, Andrzej Frycz Modrzewski Academy in Krakow

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2025 in OphthaTherapy. Therapies in Ophthalmology
Verified
Journal Article
Open access
AUAnthony Ueno
Anthony Ueno
NPNatalie Papachristoforou
Natalie Papachristoforou
IAIsmael Alsoubie
Ismael Alsoubie
JKJulia Kaczmarek
Julia Kaczmarek
MPMonika Papież
Monika Papież
MKMaciej Kozak
Maciej Kozak
Ocular toxoplasmosis (OT), a global health concern due to the protozoan T. gondii, disproportionately affects immunocompromised individuals, causing severe eye infections and potential vision loss. This review aims to evaluate current treatment options, highlighting challenges in managing both congenital and acquired forms of the infection. Our analysis synthesizes findings from 21 recent studies and a key specialty textbook, selected through systematic searches on databases including PubMed and ScienceDirect, focusing on treatments developed since 2018 to ensure relevance in the field of OT management. While diagnosis relies heavily on clinical assessments, advanced imaging like optical coherence tomography and fluorescein angiography, as well as serological and PCR testing, have improved detection. Treatment primarily involves antiparasitic and antibacterial drugs, yet standard protocols, such as pyrimethamine and sulfadiazine combinations, often fail due to severe side effects and high recurrence rates. The emergence of drug-resistant strains complicates therapy, underscoring the necessity for novel treatment approaches. Recent advancements suggest potential in mitochondrial inhibitors and histone deacetylase inhibitors, yet further research is essential to minimize toxicity and enhance specificity. OT management is hindered by the complexity of its clinical presentation and the suboptimal efficacy of traditional treatments. Personalized treatment strategies, considering patient history and local drug availability, are critical for improving outcomes in those afflicted by this debilitating infection.

22 July 2024 in OphthaTherapy. Therapies in Ophthalmology
Verified
Journal Article
Open access
PDF file
NPNatalie Papachristoforou
Natalie Papachristoforou
IAIsmael Alsoubie
Ismael Alsoubie
AUAnthony Ueno
Anthony Ueno
APAneta Pyza
Aneta Pyza
JKJulia Kaczmarek
Julia Kaczmarek
ARAnna Maria Roszkowska
Anna Maria Roszkowska
Diagnosis of malignant glaucoma presents a challenge due to subtle symptoms in early stages of the disease, making increased intraocular pressure a pivotal indicator, often accompanied by inflammation and corneal edema. Diagnostic modalities, including ultrasound biomicroscopy and anterior segment optical coherence tomography, play crucial roles in visualizing anatomical changes in the ciliary body and anterior chamber. The classic slit lamp examination, complemented by tonometry, remains a fundamental diagnostic tool. A stepwise therapeutic approach is essential, beginning with pharmacological interventions aimed at intraocular pressure reduction and subsequent restoration of the anterior chamber configuration. The first stage of treatment is pharmacotherapy. Laser therapies, such as iridotomy and Nd:YAG laser treatment, address angle closure. In resistant cases, a surgical approach, such as irydo-zonulo-hialoidotomy may be considered.

30 September 2024 in OphthaTherapy. Therapies in Ophthalmology
Verified
Journal Article
Open access
PDF file
JKJulia Kaczmarek
Julia Kaczmarek
NWNatalia Wolińska
Natalia Wolińska
APAlan Pigoński
Alan Pigoński
MPMonika Papież
Monika Papież
APAneta Pyza
Aneta Pyza
ARAnna Maria Roszkowska
Anna Maria Roszkowska
Therapeutic options in inflammatory glaucoma, both pharmacological and surgical methods, have been presented in this paper. Main goals of pharmacotherapy are: controlling inflammation and reducing intraocular pressure. Anti-inflammatory drugs primarily include topical glucocorticosteroids but also nonsteroidal anti-inflammatorydrugs and immunomodulatory therapy. Elevated intraocular pressure is treated with β-blockers, carbonic anhydrase inhibirozpotors, prostaglandin analogues and α2-adrenergic receptor agonists. If pharmacological treatment does not produce the desired results, surgical treatment must be considered. Due to the risk of reactivation of inflammation, it is recommended that it be performed 3 months after the inflammation has healed. Currently, trabeculectomy remains the gold standard. Among the invasive treatment techniques, we discuss trabeculectomy with the use of mitomycin C, micro-hook trabeculectomy, laser therapy, glaucoma drainage implants, deep sclerectomy and viscocanalostomy.

22 July 2026 in OphthaTherapy. Therapies in Ophthalmology
Verified
Journal Article
Open access
PDF file
NWNatalia Wolińska
Natalia Wolińska
JKJulia Kaczmarek
Julia Kaczmarek
MPMonika Papież
Monika Papież
APAlan Pigoński
Alan Pigoński
NPNatalie Papachristoforou
Natalie Papachristoforou
MKMaciej Kozak
Maciej Kozak
Coats disease is a rare, non-hereditary retinopathy. It is characterised by progressive destruction of the retinal blood vessels with exudates and aneurysms usually occurring unilaterally. Despite several studies, the etiology of this disease remains unclear. Treatment varies depending on the stage of the disease. Currently, laser therapy and cryocoagulation are commonly used. The disease is progressive; therefore, early diagnosis and treatment reduce the risk of severe complications.

28 November 2024 in OphthaTherapy. Therapies in Ophthalmology
Verified
Journal Article
Open access
PDF file
APAneta Pyza
Aneta Pyza
JPJakub Piórek
Jakub Piórek
IAIsmael Alsoubie
Ismael Alsoubie
NPNatalie Papachristoforou
Natalie Papachristoforou
AUAnthony Ueno
Anthony Ueno
ARAnna Maria Roszkowska
Anna Maria Roszkowska
This paper discusses scleritis in the course of systemic autoimmune diseases such as rheumatoid arthritis, nodular arteritis and granulomatosis with vasculitis. In addition, treatment suggestions based on the available literature are presented. Patients with scleritis resulting from an underlying disease should be twardiagnosed as soon as possible and given appropriate and effective treatment. Untreated or poorly treated scleritis or underlying disease can lead to severe damage to ocular tissues, loss of vision and eventually even blindness. A meticulous medical history, detailed ophthalmic examination and a series of targeted investigations as part of a multidisciplinary approach to detect any systemic disease are important in the management of scleritis. Rheumatoid arthritis remains the most common systemic rheumatic disease and the most common systemic condition associated with scleritis.